Anthera Pharmaceuticals (ANTH) Hits New 12-Month High and Low at $0.23

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) shares reached a new 52-week high and low on Thursday . The company traded as low as $0.23 and last traded at $0.23, with a volume of 17196 shares trading hands. The stock had previously closed at $0.24.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 3rd. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Jefferies Group reissued a “hold” rating and set a $0.50 target price on shares of Anthera Pharmaceuticals in a research report on Thursday, March 15th. Piper Jaffray Companies downgraded shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a report on Monday, March 12th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a report on Tuesday, March 6th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $3.44.

The firm has a market capitalization of $7.40 million, a P/E ratio of -0.06 and a beta of 2.78.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Monday, March 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.82) by $0.09. equities research analysts predict that Anthera Pharmaceuticals Inc will post -2.28 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. 683 Capital Management LLC purchased a new stake in Anthera Pharmaceuticals in the 4th quarter worth approximately $399,000. BVF Inc. IL lifted its stake in Anthera Pharmaceuticals by 20.9% in the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after purchasing an additional 209,896 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in Anthera Pharmaceuticals in the 4th quarter worth approximately $1,269,000. 8.38% of the stock is owned by institutional investors.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply